Y-90 treatment response for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests how well a Y-90 radiation treatment works for liver cancer that hasn't been treated before. It uses ultrasound imaging to check the response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive a type of radiation therapy called TARE for liver cancer that hasn't been treated before.
- You are at least 18 years old.
- Your overall health is stable.
- If you could become pregnant, you must have a negative pregnancy test before starting.
- You are willing to sign a consent form to participate.
- You do not have any allergies to the contrast agents Lumason or Sonazoid used in ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This study tests a targeted radiation treatment called Y90 for liver tumors that are too large for standard approaches. It aims to see how well the treatment works for people with primary or secondary liver cancers that mainly affect the liver and have at least one tumor bigger than 5 cm.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial gives radiation to liver tumors and then takes a small tissue sample (biopsy) to look for changes in the cancer cells after treatment. The goal is to learn what the radiation is doing inside the tumor, which may help improve future treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.